BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 29046362)

  • 21. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.
    Mattsson N; Tosun D; Insel PS; Simonson A; Jack CR; Beckett LA; Donohue M; Jagust W; Schuff N; Weiner MW;
    Brain; 2014 May; 137(Pt 5):1550-61. PubMed ID: 24625697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
    Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
    Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease.
    Levin F; Jelistratova I; Betthauser TJ; Okonkwo O; Johnson SC; Teipel SJ; Grothe MJ
    Alzheimers Res Ther; 2021 Oct; 13(1):178. PubMed ID: 34674764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of visually equivocal amyloid PET findings from the Alzheimer's Disease Neuroimaging Initiative cohort.
    Oh M; Seo M; Oh SY; Kim H; Choi BW; Oh JS; Kim JS;
    Neuroreport; 2018 May; 29(7):553-558. PubMed ID: 29438267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
    Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
    Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
    Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
    J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alzheimer's pathology targets distinct memory networks in the ageing brain.
    Maass A; Berron D; Harrison TM; Adams JN; La Joie R; Baker S; Mellinger T; Bell RK; Swinnerton K; Inglis B; Rabinovici GD; Düzel E; Jagust WJ
    Brain; 2019 Aug; 142(8):2492-2509. PubMed ID: 31199481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.
    Palmqvist S; Mattsson N; Hansson O;
    Brain; 2016 Apr; 139(Pt 4):1226-36. PubMed ID: 26936941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tau positron emission tomographic imaging in aging and early Alzheimer disease.
    Johnson KA; Schultz A; Betensky RA; Becker JA; Sepulcre J; Rentz D; Mormino E; Chhatwal J; Amariglio R; Papp K; Marshall G; Albers M; Mauro S; Pepin L; Alverio J; Judge K; Philiossaint M; Shoup T; Yokell D; Dickerson B; Gomez-Isla T; Hyman B; Vasdev N; Sperling R
    Ann Neurol; 2016 Jan; 79(1):110-9. PubMed ID: 26505746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.
    Fleisher AS; Chen K; Quiroz YT; Jakimovich LJ; Gomez MG; Langois CM; Langbaum JB; Ayutyanont N; Roontiva A; Thiyyagura P; Lee W; Mo H; Lopez L; Moreno S; Acosta-Baena N; Giraldo M; Garcia G; Reiman RA; Huentelman MJ; Kosik KS; Tariot PN; Lopera F; Reiman EM
    Lancet Neurol; 2012 Dec; 11(12):1057-65. PubMed ID: 23137949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positive rate and quantification of amyloid pathology with [
    He K; Li B; Huang L; Zhao J; Hua F; Wang T; Li J; Wang J; Huang Q; Chen K; Xu S; Ren S; Cai H; Jiang D; Hu J; Han X; Guan Y; Chen K; Guo Q; Xie F
    Eur Radiol; 2024 May; 34(5):3331-3341. PubMed ID: 37889270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
    Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
    JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study.
    Planton M; Saint-Aubert L; Raposo N; Payoux P; Salabert AS; Albucher JF; Olivot JM; Péran P; Pariente J
    J Alzheimers Dis; 2020; 73(4):1607-1614. PubMed ID: 31958082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.